Goldspan Health Tirzepatide Review: $299 Every 28 Days, Not Every Month (2026)

Goldspan Health charges $299 for compounded tirzepatide every 28 days, which is thirteen charges in a year rather than twelve. Its own site publishes no price at all; the figure sits on the storefront its product buttons hand you to, read live there on 1 September 2026.¹

The cycle the hero does not mention

The hero above the plan says $299 a month, while the plan card underneath says billed every 28 days and the timeline beside it says the order renews every four weeks. That is not a calendar month, so a year of continuous treatment costs one charge more than a monthly reading suggests.

One plan, and two formulations at the same price

There is no ladder here: one plan, no prepay tier, no introductory rung and no struck-through anchor. The injection comes with either B12 or glycine, and both cost $299, so nothing about the formulation moves the price; the sublingual microdose is $199 on the same 28-day cycle. Two costs are named but not priced: a video consultation a clinician may require, and the lab panel due 60 to 90 days after you start.

Whose company is this?

Goldspan publishes no legal entity, address or governing law of its own, and a census of its pages and its production bundle found none. The storefront that takes the money is run by a different company, Lyv Health, Inc., trading as Altro Health, whose terms are governed by Delaware law and whose address is in New York. Goldspan's own Terms say it connects customers with an independent medical group and pharmacies licensed under 503A or 503B, which states the class without naming either. The About page lists a medical director and two clinical advisers by surname alone.

How the care model holds up

What holds up is the price surface: one plan, both formulations at the same figure, the pharmacy class stated on the product page, and a named medical director and two clinical advisers on the storefront. What does not hold up is the copy around it. The homepage says the service is available in 50 states while the Terms say some therapies are unavailable in certain states, with no list of which or where. The tirzepatide sublingual microdose page's own inclusion list names semaglutide rather than tirzepatide. And the plan promises you can pause, delay or cancel at any time, while the refund policy says all sales are final once an order is placed, with one exception: a clinician who reviews your intake and declines to prescribe triggers a full refund.

The brand-vs-compounded question

This is compounded tirzepatide, not Zepbound, and Goldspan sells no brand product. Compounding happens at a pharmacy, produces no FDA-approved finished product, and puts the vial outside what the pivotal trials measured. Our guide to whether compounded tirzepatide is still legal in 2026 covers where that stands.

Does the drug work? (Separate from the provider)

Price and billing are the seller's problem; efficacy is the molecule's, and tirzepatide's record is strong. SURMOUNT-1 put weight loss at roughly 15% to 21% of body weight over 72 weeks², and SURMOUNT-5 placed it ahead of semaglutide head to head³, both on the approved brand product. Our tirzepatide evidence guide has the full picture.

The honest verdict

The price is public before any intake, one plan means nothing to decode, and the Terms at least state the pharmacy class. Set against that: a 28-day cycle sold as a month, a brand with no entity behind it, and a cancel-anytime promise sitting on top of a final-sale policy. Lean Meds charges $109 a month with its four pharmacies named outright, the disclosure Goldspan stops one step short of. Magnolia Regenerative Medicine publishes an address, charges $199 a month and runs two clinics you can walk into. The ranked best tirzepatide providers list sets all three against the field.